Pricing The Side Effects Of Prostate Cancer Treatment

Published Jun 17, 2012

Diemen, The Netherlands - Increased sharing of information across jurisdictions regarding the assessments of pharmaceuticals may save costs and reduce duplication of efforts.

Assessment of the clinical effectiveness of (new) pharmaceuticals compared to alternative treatment(s) is important in many jurisdictions for determining the reimbursement status of pharmaceuticals. This type of assessment is also known as relative effectiveness assessment (REA). We have studied the main similarities and differences in the major methodological aspects of REA in 29 jurisdictions. There seem to be substantial similarities on the choice of the comparator, the role of indirect comparisons, and preferred clinical endpoints. This article, “Relative Effectiveness Assessment of Pharmaceuticals: Similarities and Differences in 29 Jurisdictions” will be published inValue in Health, the official journal of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Wim Goettsch, project leader of work package five of EUnetHTA, says that, “if we want to move forward with European collaboration, shared methods and best practices for REA between jurisdictions will be a necessary first step. Our study shows that important methodological aspects are approached in a similar way in many jurisdictions, indicating that there is a basis for advanced collaboration.”

Value in Health (ISSN 1098-3015) publishes papers, concepts, and ideas that advance the field of pharmacoeconomics and outcomes research as well as policy papers to help health care leaders make evidence-based decisions. The journal is published bi-monthly and has over 8,000 subscribers (clinicians, decision makers, and researchers worldwide).

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is a nonprofit, international, educational and scientific organization that strives to increase the efficiency, effectiveness, and fairness of health care resource use to improve health. For more information:

Related Stories

Measuring What Matters: Broadening the Scope of Health Economics Evaluation to Incorporate Well-Being

Jul 9, 2024

ISPOR announced the publication of a special themed section of research papers in Value in Health that offer insights into facets of economic evaluation aimed to incorporate well-being into decision making.

Confronting the Backlash Against QALYs: Key Insights From Leading Health Economists

Jun 18, 2024

ISPOR announced the publication of a collection of papers that examine the long-standing debate surrounding the use of quality-adjusted life years (QALYs) and alternative measures in healthcare decision making.

ISPOR Good Practices Report Offers Guidance for Using Real-World Data From EHRs in Health Technology Assessments

Jun 17, 2024

ISPOR announced the publication of an ISPOR Good Practices Report that proposes a framework for assessing the suitability of electronic health records data for use in health technology assessments. The report, “Assessing Real-World Data from Electronic Health Records for Health Technology Assessment: The SUITABILITY Checklist: A Good Practices Report of an ISPOR Task Force” was published in the June 2024 issue of Value in Health.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on Update my browser now